Read or download the full Economic Impact Assessment report Read more
Laverock Therapeutics raises £13.5M to develop unique gene silencing platform for programmable advanced therapies
Published on 28 Sep 2023
Pharmidex part of consortium to receive €4m Eurostars grant
Published on 20 Sep 2023
Andrew Waters appointed Chief Financial Officer
Published on 20 Sep 2023
Dr Sally Ann Forsyth OBE awarded Honorary Doctorate in Science
Published on 6 Sep 2023
Cell and Gene Therapy Catapult, Rentschler Biopharma and Refeyn collaborate to improve process analytical technologies and AAV manufacturing for gene therapies
Published on 23 Aug 2023
UBS Asset Management and Reef Group secure approval for one of Europe’s largest Life Science campuses in Stevenage
Published on 9 Aug 2023
Plasticell, Cell and Gene Therapy Catapult and Imperial College London obtain funding to develop manufacturing platform for allogeneic cell immunotherapies
Published on 8 Aug 2023
Autolus case study: From early-stage research company to a robust clinical-stage development and manufacturing company
Published on 27 Jul 2023
Class of 2023 SBC Catalyser Programme ‘graduate’ with flying colours
Published on 20 Jul 2023
Cytiva launches first formulation system to enable end-to-end clinical and commercial manufacturing of lipid nanoparticle medicines
Published on 13 Jul 2023
Medicines and Healthcare products Regulatory Agency authorises GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for older adults
Published on 10 Jul 2023
Medicines and Healthcare products Regulatory Agency authorises GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for older adults
Published on 10 Jul 2023
Groundbreaking new £100m LifeArc programme aims to improve the lives of people living with a rare disease
Published on 6 Jul 2023
New UK-based research project brings together world-leading institutions to transform care for people living with dementia
Published on 29 Jun 2023
Cytiva and BioCentriq awarded NIIMBL funding to accelerate bringing gene therapies to market
Published on 27 Jun 2023
New programme to move potential MND drugs into clinical trials faster
Published on 21 Jun 2023
Autolus Therapeutics strengthens its Board with the appointment of Dr. Robert Iannone as a Non-Executive Director
Published on 20 Jun 2023
Culture Biosciences and Cytiva team up to innovate in upstream bioprocessing to advance the development and manufacturing of new therapies
Published on 15 Jun 2023
Complement Therapeutics Unveils State-of-the-Art Laboratory at Stevenage Bioscience Catalyst
Published on 13 Jun 2023
Location, Location, Location: The Key Ingredients for the Success of Cell and Gene Cluster Excellence and the Future of the Sector
Published on 12 Jun 2023
Quell Therapeutics Signs a Collaboration, Exclusive Option and License Agreement with AstraZeneca to Develop, Manufacture and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases
Published on 9 Jun 2023

Copyright © 2023 Stevenage Bioscience Catalyst

Designed and built by Onespacemedia

We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.